Phase I Multi-Center Study Of Stereotactic Ablative Radiotherapy (SABR) In Combination With Durvalumab And Tremelimumab In Patients With Recurrent/Metastatic Advanced Cervical, Vaginal, Or Vulvar Cancer
MD Anderson Study Status
Tremelimumab, MEDI4736, Durvalumab
This phase I trial studies how well stereotactic body radiation therapy works in combination with tremelimumab and durvalumab in treating participants with cervical, vaginal, or vulvar cancers that have come back (recurrent) or spread to other areas of the body (metastatic). Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as tremelimumab and durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving stereotactic body radiation therapy, tremelimumab, and durvalumab may work better in treating participants with cervical, vaginal, or vulvar cancers.
Information and next steps
For general questions about clinical trials: